Curriculum vitae
Personal data:
Torben Plesner
Born on 28. February 1947.
Medical Degree : University of Copenhagen.
First part : 1968. Second part : 1972.
Clinical qualifications:
Consultant in Hematology, Department of Hematology, Herlev
Hospital 1. March 1993 – 30. September 2000
Consultant in Hematology and Head of the Department of
Hematology, Section of Internal Medicine, Vejle Hospital, Vejle,
Denmark and Lecturer at the University of Southern Denmark 1.
October 2000 Certified as clinical chemistry (MD) Specialist in Denmark, 1981.
Certified as internal medicine Specialist in Denmark, 1989.
Certified as Specialist in hematology in Denmark, 1990.
Academic achievements:
Thesis accepted by University of Copenhagen July, 1981
in fulfillment of Doctor of Medical Sciences degree.
Thesis title : "Immunochemical Studies of Human β2Microglobulin. A Review of Recent Methodological
Progress and Clinical Applications".
Per review publications in journals from
Key publications:
Ploug M, Plesner T, Rønne E, Ellis V, Høyer-Hansen G, Hansen NE, Danø K.
The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in
patients with paroxysmal nocturnal hemoglobinuria.
Blood. 1992 Mar 15;79(6):1447-55.
Ploug M, Eriksen J, Plesner T, Hansen NE, Danø K.
A soluble form of the glycolipid-anchored receptor for urokinase-type plasminogen activator is
secreted from peripheral blood leukocytes from patients with paroxysmal nocturnal hemoglobinuria.
Eur J Biochem. 1992 Sep 1;208(2):397-404.
Plesner T, Ploug M, Ellis V, Rønne E, Høyer-Hansen G, Wittrup M, Pedersen TL, Tscherning T, Danø
K, Hansen NE.
The receptor for urokinase-type plasminogen activator and urokinase is translocated from two distinct
intracellular compartments to the plasma membrane on stimulation of human neutrophils.
Blood. 1994 Feb 1;83(3):808-15.
Standal T, Seidel C, Hjertner Ø, Plesner T, Sanderson RD, Waage A, Borset M, Sundan A.
Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.
Blood. 2002 Oct 15;100(8):3002-7.
Boissy P, Andersen TL, Abdallah BM, Kassem M, Plesner T, Delaissé JM.
Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast
differentiation.
Cancer Res. 2005 Nov 1;65(21):9943-52.
Andersen TL, Boissy P, Sondergaard TE, Kupisiewicz K, Plesner T, Rasmussen T, Haaber J, Kølvraa
S, Delaissé JM.
Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell
clone: a new type of cancer-host partnership?
J Pathol. 2007 Jan;211(1):10-7.
Christensen JH, Abildgaard N, Plesner T, Nibe A, Nielsen O, Sørensen AG, Kerndrup GB;
Leukemia/Lymphoma Study Group, Region of Southern Denmark.
Interphase fluorescence in situ hybridization in multiple myeloma and monoclonal gammopathy of
undetermined significance without and with positive plasma cell identification: analysis of 192 cases
from the Region of Southern Denmark.
Cancer Genet Cytogenet. 2007 Apr 15;174(2):89-99.
Boissy P, Andersen TL, Lund T, Kupisiewicz K, Plesner T, Delaissé JM.
Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in
clinically relevant conditions.
Leuk Res. 2008 Apr 2 (in press)
Sondergaard T.E., Pedersen P.T., Andersen T.L., Søe K., Lund T., Østergaard B., Garnero P., Delaisse
J-M., Plesner T.
A phase II clinical trial does not show that high dose simvastatin has beneficial effect on markers of
bone turnover in multiple myeloma.
Hematological oncology , in press June 2008.
T. L. Andersen, T. E. Sondergaard, K. E. Skorzynska, F. Dagnaes-Hansen, T.L. Plesner, E. Hauge, T.
Plesner, J. M. Delaisse.
A physical mechanism for coupling of bone resorption and formation in adult human bone.
Submitted for publication June 2008.
Teaching:
Specialist training in Hematology for residents in Hematology – assistant course leader since 2006
Administrative qualifications:
Head of the Department of Hematology, Vejle Hospital and founder of the departments Clinical
Research Unit
Research supervision:
Doctors thesis (D.M.Sci., University of Copenhagen):
Mogens Holst Nissen:”Proteolytic modification of β2-microglobulin in human serum”. 1992.
Carsten Geisler:”The T-cell receptor. Structural and functional studies”. 1995.
PhD studies (principal supervisor):
Minna Wittrup:”Receptoren for urokinase plasminogen aktivator på humane blodceller”. University
of Copenhagen. 1995.
Anne Helmer Jakobsen:”Resistensudvikling og P-glykoprotein ekspression ved cytostatisk behandling
af humane leukæmi cellelinier”. University of Copenhagen. 1996.
Teis E. Søndergaard: “The effect of statin on bone markers in multiple myeloma and a description of
the bone remodeling compartment”. University of Southern Denmark, submitted 2008.
Katarzyna Kupisiewicz: “Resveratrol analogs for treating multiple myeloma and related bone disease.
Effects on myeloma cells, osteoclasts, and osteoblasts, in vitro and in vivo”. University of Southern
Denmark, ongoing study.
Thomas Lund:“Knoglemarkører ved myelomatose. / Bone markers in Multiple Myeloma”. University of
Southern Denmark, ongoing study.
Speciality study (University of Copenhagen):
Johannes Aslo-Petersen: ”Fremstilling og karakterisering af peptidspecifikke antistoffer mod Pglykoprotein”.1994.